Fibrosis Development News Today

Results add to the growing body of evidence and reinforce the efficacy profile of Sotyktu, a once-daily, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of moderate-to-severe plaque psoriasisNew analysis to be presented at the 2022 European Academy of Dermatology and Venereology Cong...

Results showed improved or preserved cognitive function in a majority of people regardless of baseline values, with the greatest effect observed in almost 80% of people with high thalamic volume (45.5%

Press release content from Business Wire. The AP news staff was not involved in its creation.

Deucravacitinib showed statistically significant efficacy at primary endpoint of Systemic Lupus Erythematosus (SLE) Responder Index-4 (SRI(4)) responses versus placebo at Week 32 Secondary endpoints

Treatment with deucravacitinib was associated with long-term efficacy and safety in adults with moderate to severe plaque psoriasis.

Kisspeptin hormone is found to have another promising function beyond puberty and fertility. Find out what it does against non-alcoholic fatty liver disease.

In Crohn’s disease (CD), intestinal fibrosis is a critical determinant of a patient’s prognosis. Although inflammation may be a prerequisite for the initiation of intestinal fibrosis, research shows that the progression or continuation of intestinal fibrosis can occur independently of inflammation. Thus, once initiated, intestinal fibrosis may persist even if medical treatment controls inflammation. Clearly, an understanding of the pathophysiological mechanisms of intestinal fibrosis is requ...

The FDA has accepted for review the New Drug Application for deucravacitinib for the treatment of adults with moderate to severe plaque psoriasis.

NEW YORK CITY (dpa-AFX) - Bristol Myers Squibb (BMY) said on Tuesday that the European Commission or EC has granted marketing authorization for ozanimod, brand named Zeposia for the treatment of

Research to be presented on Orencia, deucravacitinib and pipeline assets highlights breadth of data and focus on transforming treatment paradigms for people living with rheumatic diseases Bristol Myers Squibb today announced data from 29 company-sponsored presentations across Orencia, deucravacitinib and pipeline assets will be presented at the American College of Rheumatology Convergence 2021, taking place ...